Search

Rocket Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

3.47 4.2

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.27

Maximum

3.49

Fő mutatók

By Trading Economics

Bevétel

171M

123M

Egy részvényre jutó nyereség

-0.15

Munkavállalók

202

EBITDA

-1.9M

-47M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+234.43% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

3.3M

397M

Előző nyitás

-0.73

Előző zárás

3.47

Hangulat hírek alapján

By Acuity

27%

73%

97 / 340 Rangsor szerint Healthcare

Rocket Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 22:01 UTC

Rocket Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified. Broader market concerns may be influencing the decline.

2026. aug. 13. 19:56 UTC

Rocket Pharmaceuticals Inc shares are lower today, continuing a recent downward trend amid rising U.S. unemployment claims, with no specific company news identified.

2026. aug. 12. 19:16 UTC

Rocket Pharmaceuticals Inc shares are lower today, with no specific news driving the decline. Earlier, the stock reached a session high before falling.

2026. aug. 11. 20:02 UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

2026. aug. 10. 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

2026. aug. 8. 00:01 UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

2026. aug. 7. 23:01 UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

2026. aug. 6. 23:06 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

2026. aug. 5. 20:02 UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

2026. aug. 4. 19:26 UTC

News
Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

2026. aug. 3. 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

2026. júl. 31. 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

2026. júl. 30. 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2026. júl. 29. 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

2026. júl. 28. 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

2026. júl. 27. 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

2026. júl. 24. 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

2026. júl. 22. 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

2026. júl. 20. 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Társak összehasonlítása

Árváltozás

Rocket Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

234.43% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 11.17 USD  234.43%

Magas 15 USD

Alacsony 5 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Rocket Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

8 ratings

5

Vétel

3

Tartás

0

Eladás

Hangulat

By Acuity

97 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat